Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2699]
News [7554]
Articles [308]
Editorials [8]
Conferences [228]
elearning [48]
The concept of time toxicity: A patient's perspective
Dr Christopher Booth - Queen's University, Kingston, Canada
The concept of time toxicity: A patient's perspective ( Dr Christopher Booth - Queen's University, Kingston, Canada )
19 Sep 2022
ESMO 2022: Breast and ovarian trial analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
14 Sep 2022
Latest in mRCC from ESMO 2022
Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane...
Latest in mRCC from ESMO 2022 ( Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Oudard )
12 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC
Dr Silvia Novello - University of Turin, Turin, Italy
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )
12 Sep 2022
ESMO 2022: Renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ESMO 2022: Renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast...
Prof Matthew P Goetz - Mayo Clinic, Rochester, USA
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )
12 Sep 2022
Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple...
Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands
Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer ( Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands )
12 Sep 2022
Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum...
Prof Siow-Ming Lee - University College London, London, UK
Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen ( Prof Siow-Ming Lee - University College London, London, UK )
12 Sep 2022
Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in...
Prof Siow-Ming Lee - University College London, London, UK
Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC ( Prof Siow-Ming Lee - University College London, London, UK )
12 Sep 2022
RADICALS-HD trial: androgen deprivation therapy with post-operative...
Prof Chris Parker - Institute of Cancer Research, Sutton, UK
RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )
12 Sep 2022
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer
Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )
11 Sep 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation